AbbVie Inc. ($ABBV) Stock Forecast: Up 7.8% Today

What is AbbVie Inc.?

ABBV Stock: Bullish Movement AbbVie is a pharmaceutical company focusing on developing treatments in immunology, oncology, and neuroscience. The company boasts a diverse drug portfolio and a robust pipeline of innovative therapies.

Why is AbbVie Inc. going up?

ABBV stock is up 7.8% on Apr 30, 2026 13:40

• The bullish movement in AbbVie's stock is linked to its philanthropic partnership with Allergan Aesthetics, demonstrating a dedication to social responsibility and community involvement.
• The price target increase by Goldman Sachs signifies confidence in AbbVie's growth potential, especially with successful products like Skyrizi and Rinvoq and promising pipeline updates.
• AbbVie's positive outlook might have been reinforced by a competitor's underperformance, showcasing AbbVie's strength within the pharmaceutical sector.
• In conclusion, AbbVie's strategic efforts, strong product performance, and favorable analyst evaluations appear to have influenced the upward trend in its stock price.

ABBV Price Chart

ABBV Technical Analysis

ABBV News

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Allergan Aesthetics, an AbbVie company, announced a charitable initiative for Skin Cancer Awareness Month. They will donate $10 to The Skin Cancer Foundation for every new member who joins their Allē loyalty program through a referral in May, up to $100,000. This effort aims to promote education and prevention of skin cancer, highlighting the importance of daily habits like sunscreen use and regular skin checks.

https://news.abbvie.com/2026-04-30-Allergan-Aesthetics-Launches-Philanthropic-Effort-in-Recognition-of-Skin-Cancer-Awareness-Month

Netflix, Adobe OK $25B Buybacks; Blackstone Backs Teva

Netflix and Adobe have each authorized new $25 billion share repurchase programs, with Netflix's plan having no expiration and Adobe's running through 2030. While Netflix's buyback is seen as offensive, Adobe's comes as the company faces AI disruption fears, leading to a muted market reaction. In contrast, Blackstone Life Sciences is investing up to $400 million in Teva Pharmaceuticals for its duvakitug development, showcasing a growth-focused partnership instead of capital return.

https://www.heygotrade.com/en/news/netflix-adobe-25b-buyback-blackstone-teva-400m-2026/

Goldman Sachs raises Abbvie stock price target on growth confidence

Goldman Sachs increased its price target for AbbVie (NYSE:ABBV) to $244 from $240, reaffirming a Neutral rating, based on management's confident outlook following Q1 2026 results. The firm cited strong performance expectations for Skyrizi and Rinvoq through 2031 and positive pipeline updates for various therapies. Despite a year-to-date decline in stock price, AbbVie's dividend yield and consecutive increases continue to attract investors, though InvestingPro data suggests the stock is currently overvalued.

https://www.investing.com/news/analyst-ratings/goldman-sachs-raises-abbvie-stock-price-target-on-growth-confidence-93CH-4648103

Amgen Inc. Stock (US0311621009): Reports Strong Q1 2026 Results with Revenue Beat

Amgen Inc. reported strong first-quarter 2026 results, surpassing revenue expectations with $8.3 billion, a 12% increase year-over-year, driven by top-performing drugs like Enbrel and Prolia. The biotech company also reaffirmed its full-year guidance and saw adjusted EPS of $5.15, beating consensus estimates. Analysts from RBC Capital and JPMorgan maintained positive ratings, with price targets of $350 and $340 respectively, indicating confidence in Amgen's pipeline and market performance despite future patent expiry risks.

https://www.ad-hoc-news.de/boerse/news/ueberblick/amgen-inc-stock-us0311621009-reports-strong-q1-2026-results-with/69262591

Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

Regeneron Pharmaceuticals Inc. (REGN) shares fell on Wednesday, underperforming its competitors. The stock closed down $21.57, or 2.29%, at $921.90, while the S&P 500 also saw a decline. This performance stands in contrast to some of its rivals in the pharmaceutical industry.

https://www.msn.com/en-us/money/topstocks/regeneron-pharmaceuticals-inc-stock-underperforms-wednesday-when-compared-to-competitors/ar-AA221PEs

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.1% Today

Solana ($SOL) Crypto Forecast: Down 5.6% Today

Advance Auto Parts Inc W/I ($AAP) Stock Forecast: Down 5.1% Today

NRG Energy Inc. ($NRG) Stock Forecast: Down 5.0% Today

Ubiquiti ($UI) Stock Forecast: Down 5.2% Today

Franco-Nevada Corp. ($FNV) Stock Forecast: Down 5.2% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Up 11.1% Today

Ford Motor Company ($F) Stock Forecast: Down 7.1% Today

ServiceNow Inc. ($NOW) Stock Forecast: Up 5.0% Today

Kornit Digital Ltd. ($KRNT) Stock Forecast: Down 5.4% Today

AbbVie Inc. Price History

29.03.2026 - ABBV Stock was up 3.2%

• AbbVie surpassed expectations for the first quarter of 2026, achieving net revenues of $15.002 billion, representing a 12.4% increase. The growth was mainly credited to the success of newer immunology medications like Skyrizi and Rinvoq, which offset the sales decline of Humira due to patent expiration.
• The company revised its full-year 2026 adjusted EPS guidance upwards, indicating confidence in its pipeline progress and core business. This optimistic outlook was reinforced by substantial growth in the neuroscience portfolio, notably with Botox Therapeutic surpassing $1 billion in quarterly sales for the first time.
• Investors reacted positively to AbbVie's impressive performance, being reassured by the company's adept handling of challenges like patent expiration and its ability to capitalize on innovative products to propel growth.
• AbbVie's strategic emphasis on developing and launching new medications, along with its continual investments in manufacturing and pipeline advancements, positions the company strongly for ongoing success in the pharmaceutical sector.

18.02.2026 - ABBV Stock was down 5.2%

• ABBV stock saw a 5% drop post the FDA approval of J&J's Icotyde, a new oral plaque psoriasis treatment, creating direct competition with AbbVie's Skyrizi.
• Analysts predict a 23% increase in Skyrizi sales by FY2026, notwithstanding the competition, showcasing some strength in AbbVie's market position.
• The decrease in ABBV stock value can be linked to worries regarding Icotyde's impact on Skyrizi's market presence, compounded by ongoing challenges from Humira's loss of exclusivity and falling aesthetics segment sales.
• With Icotyde's approval as a convenient oral option with high effectiveness compared to injectables, it presents a significant challenge to AbbVie's dominance in the psoriasis treatment sector, leading to a pessimistic outlook on ABBV stock.

18.02.2026 - ABBV Stock was down 5.0%

• The current downward movement in ABBV stock may be linked to significant reductions in holdings by Wilmington Savings Fund Society FSB, offloading 26,080 shares in the third quarter, as well as insider selling of substantial stakes.
• Despite AbbVie surpassing quarterly expectations and offering robust FY2026 guidance, the selling activities by major institutions and insiders could have triggered investor apprehensions, contributing to the current bearish trend.
• Information regarding Johnson & Johnson's FDA approval for a new oral psoriasis pill, Icotyde, creating competition in the psoriasis market, might have also impacted investor confidence in AbbVie's future market share and revenue potential.

18.02.2026 - ABBV Stock was down 5.2%

• Wilmington Savings Fund Society FSB notably decreased its stake in AbbVie Inc., selling off a significant number of shares, which might reflect a lack of confidence in the company's future.
• Despite AbbVie's outperformance in the last quarter and positive guidance for FY2026, concerns raised by a business health analysis regarding sluggish sales growth and declining financial metrics might have driven the bearish movement.
• The high payout ratio of 293.22%, resulting from a quarterly dividend of $1.73 per share, may have added to investor worries, particularly as insiders in leadership positions were observed selling portions of their shares.
• Danske Bank A S's substantial investment in AbbVie Inc. stands in contrast, potentially indicating divergent views on the stock's performance and future prospects.

18.02.2026 - ABBV Stock was down 5.4%

• AbbVie's stock experienced a significant 4.60% decline on March 18, driven by various factors including:
• Intense competition: Approval of a new oral peptide for psoriasis poses a direct threat to AbbVie's Skyrizi, impacting investor sentiment negatively.
• Biosimilar competition: Ongoing pressure from biosimilar competition for its blockbuster drug Humira continues to weigh on AbbVie's stock performance.
• Weakness in aesthetics business: Challenges in AbbVie's aesthetics business segment also contributed to the bearish movement of the stock.
• Despite some positive developments in AbbVie's pipeline, the combination of these factors led to a correction and weakening trend momentum in the stock price.
• The approval of a new drug by the FDA and its potential as a blockbuster drug with significant sales projections added further pressure on AbbVie's stock, highlighting the competitive landscape in the pharmaceutical industry.

05.00.2026 - ABBV Stock was down 2.6%

• Today's bearish movement in AbbVie's stock price can be attributed to several factors:
• Despite strong Q3 earnings and dividend increases, the reduction in holdings by institutional investors like Railway Pension Investments Ltd and Commonwealth Equity Services LLC may have signaled concerns about the company's future growth prospects.
• The $100 million upfront investment in the trispecific lung cancer drug ZG006, while positioning AbbVie to challenge competitors like Amgen, might have raised investor worries about the high costs and risks associated with drug development.
• The upcoming presentation at the J.P. Morgan Healthcare Conference could have led to profit-taking by some traders who may have been expecting more significant announcements or guidance from the management.
• The overall market sentiment towards pharmaceutical companies and healthcare stocks today might have also played a role in the bearish movement of AbbVie's stock, as investors may be rotating their portfolios based on sector performance and economic outlook.

04.01.2026 - ABBV Stock was down 8.6%

• AbbVie surpassed analyst estimates with its financial performance in Q4 2025, including strong revenue figures and a notable showing by Humira.
• Despite the optimistic earnings report and an increased profit forecast for 2026, the stock saw a minor decline, potentially influenced by investors taking profits following recent positive developments.
• Market response indicates that notwithstanding the company's positive outlook and solid performance, investors may have held elevated expectations or concerns regarding the future earnings impact of Humira's patent expiration.
• The slight drop in the stock price might also be linked to general market conditions or specific challenges within the pharmaceutical sector affecting investor sentiment.

30.03.2026 - ABBV Stock was up 7.8%

• The bullish movement in AbbVie's stock is linked to its philanthropic partnership with Allergan Aesthetics, demonstrating a dedication to social responsibility and community involvement.
• The price target increase by Goldman Sachs signifies confidence in AbbVie's growth potential, especially with successful products like Skyrizi and Rinvoq and promising pipeline updates.
• AbbVie's positive outlook might have been reinforced by a competitor's underperformance, showcasing AbbVie's strength within the pharmaceutical sector.
• In conclusion, AbbVie's strategic efforts, strong product performance, and favorable analyst evaluations appear to have influenced the upward trend in its stock price.

07.00.2026 - ABBV Stock was up 5.1%

• AbbVie's price target was increased to $240 by UBS, reflecting optimism about the company's performance.
• GuruFocus forecasts a possible downside for ABBV, indicating mixed perspectives on the stock.
• The positive outlook for AbbVie's growth potential and position in the pharmaceutical sector could be driving the bullish trend.
• The stock's upward momentum may be a response to the news of the raised price target, garnering favorable investor reactions.

08.00.2026 - ABBV Stock was down 5.3%

• AbbVie's stock decreased after lowering its Q4 and full-year 2025 guidance, receiving a downgrade from Wolfe Research, and refuting acquisition discussions with Revolution Medicines. These developments likely influenced the bearish movement.
• Xilio Therapeutics raised $35.8 million through warrant exercises and met a development milestone with AbbVie, providing positive news for Xilio amidst AbbVie's challenges, potentially shifting investor focus.
• AbbVie's denial regarding Revolution Medicines acquisition rumors, following a surge in Revolution's stock, contributed to market volatility and potentially impacted AbbVie's stock decline.
• Market sentiment towards pharmaceutical companies and their strategic decisions, exemplified by the varied news on AbbVie and Revolution Medicines, may have also influenced AbbVie's stock performance today.